IR Calendar | RaQualia Pharma Inc.

2012

2012

2012. 02. 16
Summary of 2011 Settlement of Accounts
2012. 02. 20
Presentation Meeting for 2011 Settlement of Accounts
2012. 03. 29
Annual General Meeting of Shareholders for the Fourth Fiscal Year
2012. 05. 11
Summary of First Quarter 2012 Finantial Results
2012. 08. 10
Summary and Explanatory Meeting for the Second Quarter 2012 Settlement of Accounts
2012. 11. 09
Summary for the Third Quarter 2012 Settlement of Accounts

*This schedule is subject to change.

Corporate Information: CEO Message; Company Overview; Vision, Management Principle and Culture; Corporate Governance; Business Model; Origins of Our Corporate Name and Logo; Facilities; Access; Press Release
Research & Development: Collaboration; Partnering in Research; What are Research Tools?; Research Tool Licensing

Product Information: Anidulafungin; Ziprasidone; Dalbavancin; EP₄ Antagonist; Cyclooxygenase-2 (COX-2) Inhibitor; Ghrelin Receptor Agonist; 5-HT₄ Partial Agonist; Acid Pump Antagonist; 5-HT_2B Antagonist; CB₂ Agonist; Motilin Receptor Agonist; Licensing

Shareholder and Investor Information

To our Shareholders and Investors

Vision, Management Principle and Culture

Corporate Governance

Outline of Securities Matters

IR Related News

Understanding RaQualia Pharma! RaQualia FAQ: RaQualia's History; What does RaQualia Pharma do?; How Does RaQualia Earn Revenues?; What About Dividends?; What are RaQualia's strengths?; What Does the Future Hold for RaQualia Pharma?

Corporate Introduction Video
Contributions to Society: Corporate Contributions; Contributions to the Community; Press Release; Topics